415 related articles for article (PubMed ID: 16827902)
1. A dual altered peptide ligand down-regulates myasthenogenic T cell responses and reverses experimental autoimmune myasthenia gravis via up-regulation of Fas-FasL-mediated apoptosis.
Aruna BV; Ben-David H; Sela M; Mozes E
Immunology; 2006 Jul; 118(3):413-24. PubMed ID: 16827902
[TBL] [Abstract][Full Text] [Related]
2. A dual altered peptide ligand inhibits myasthenia gravis associated responses by inducing phosphorylated extracellular-regulated kinase 1,2 that upregulates CD4+CD25+Foxp3+ cells.
Ben-David H; Venkata Aruna B; Sela M; Mozes E
Scand J Immunol; 2007 Jun; 65(6):567-76. PubMed ID: 17523950
[TBL] [Abstract][Full Text] [Related]
3. Down-regulation of T cell responses to AChR and reversal of EAMG manifestations in mice by a dual altered peptide ligand via induction of CD4+ CD25+ regulatory cells.
Aruna BV; Sela M; Mozes E
J Neuroimmunol; 2006 Aug; 177(1-2):63-75. PubMed ID: 16757035
[TBL] [Abstract][Full Text] [Related]
4. The nature of the active suppression of responses associated with experimental autoimmune myasthenia gravis by a dual altered peptide ligand administered by different routes.
Paas-Rozner M; Sela M; Mozes E
Proc Natl Acad Sci U S A; 2001 Oct; 98(22):12642-7. PubMed ID: 11606745
[TBL] [Abstract][Full Text] [Related]
5. A dual altered peptide ligand down-regulates myasthenogenic T cell responses by up-regulating CD25- and CTLA-4-expressing CD4+ T cells.
Paas-Rozner M; Sela M; Mozes E
Proc Natl Acad Sci U S A; 2003 May; 100(11):6676-81. PubMed ID: 12743364
[TBL] [Abstract][Full Text] [Related]
6. Down-regulation of myasthenogenic T cell responses by a dual altered peptide ligand via CD4+CD25+-regulated events leading to apoptosis.
Ben-David H; Sela M; Mozes E
Proc Natl Acad Sci U S A; 2005 Feb; 102(6):2028-33. PubMed ID: 15677327
[TBL] [Abstract][Full Text] [Related]
7. A 50-kDa ERK-like protein is up-regulated by a dual altered peptide ligand that suppresses myasthenia gravis-associated responses.
Ben-David H; Aruna BV; Seger R; Sela M; Mozes E
Proc Natl Acad Sci U S A; 2006 Nov; 103(48):18232-7. PubMed ID: 17108079
[TBL] [Abstract][Full Text] [Related]
8. Oral administration of a dual analog of two myasthenogenic T cell epitopes down-regulates experimental autoimmune myasthenia gravis in mice.
Paas-Rozner M; Dayan M; Paas Y; Changeux JP; Wirguin I; Sela M; Mozes E
Proc Natl Acad Sci U S A; 2000 Feb; 97(5):2168-73. PubMed ID: 10681457
[TBL] [Abstract][Full Text] [Related]
9. The role of CD8+CD28 regulatory cells in suppressing myasthenia gravis-associated responses by a dual altered peptide ligand.
Ben-David H; Sharabi A; Dayan M; Sela M; Mozes E
Proc Natl Acad Sci U S A; 2007 Oct; 104(44):17459-64. PubMed ID: 17956982
[TBL] [Abstract][Full Text] [Related]
10. Immunomodulation by a dual altered peptide ligand of autoreactive responses to the acetylcholine receptor of peripheral blood lymphocytes of patients with myasthenia gravis.
Dayan M; Sthoeger Z; Neiman A; Abarbanel J; Sela M; Mozes E
Hum Immunol; 2004 Jun; 65(6):571-7. PubMed ID: 15219376
[TBL] [Abstract][Full Text] [Related]
11. An altered peptide ligand inhibits the activities of matrix metalloproteinase-9 and phospholipase C, and inhibits T cell interactions with VCAM-1 induced in vivo by a myasthenogenic T cell epitope.
Faber-Elmann A; Grabovsky V; Dayan M; Sela M; Alon R; Mozes E
FASEB J; 2001 Jan; 15(1):187-194. PubMed ID: 11149906
[TBL] [Abstract][Full Text] [Related]
12. Cytokine profile and T cell adhesiveness to endothelial selectins: in vivo induction by a myasthenogenic T cell epitope and immunomodulation by a dual altered peptide ligand.
Faber-Elmann A; Grabovsky V; Dayan M; Sela M; Alon R; Mozes E
Int Immunol; 2000 Dec; 12(12):1651-8. PubMed ID: 11099304
[TBL] [Abstract][Full Text] [Related]
13. Changes in sensitivity of peripheral lymphocytes of autoimmune gld mice to FasL-mediated apoptosis reveal a mechanism for the preferential deletion of CD4-CD8-B220+ T cells.
Xiao S; Zhang X; Mann KK; Jodo S; Li L; Jarjour WN; Marshak-Rothstein A; Sherr DH; Ju ST
Int Immunol; 2004 May; 16(5):759-66. PubMed ID: 15096479
[TBL] [Abstract][Full Text] [Related]
14. Fas/Fas ligand pathway, apoptosis, and clonal anergy involved in systemic acetylcholine receptor T cell epitope tolerance.
Deng C; Goluszko E; Christadoss P
J Immunol; 2001 Mar; 166(5):3458-67. PubMed ID: 11207304
[TBL] [Abstract][Full Text] [Related]
15. Abnormal Fas/FasL and caspase-3-mediated apoptotic signaling pathways of T lymphocyte subset in patients with systemic lupus erythematosus.
Xue C; Lan-Lan W; Bei C; Jie C; Wei-Hua F
Cell Immunol; 2006 Feb; 239(2):121-8. PubMed ID: 16808908
[TBL] [Abstract][Full Text] [Related]
16. Suppression of myasthenogenic responses of a T cell line by a dual altered peptide ligand by induction of CD4+CD25+ regulatory cells.
Aruna BV; Sela M; Mozes E
Proc Natl Acad Sci U S A; 2005 Jul; 102(29):10285-90. PubMed ID: 16014414
[TBL] [Abstract][Full Text] [Related]
17. Cholangiocarcinomas express Fas ligand and disable the Fas receptor.
Que FG; Phan VA; Phan VH; Celli A; Batts K; LaRusso NF; Gores GJ
Hepatology; 1999 Dec; 30(6):1398-404. PubMed ID: 10573518
[TBL] [Abstract][Full Text] [Related]
18. Intracellular mechanisms mediating tocotrienol-induced apoptosis in neoplastic mammary epithelial cells.
Sylvester PW; Shah S
Asia Pac J Clin Nutr; 2005; 14(4):366-73. PubMed ID: 16326643
[TBL] [Abstract][Full Text] [Related]
19. The role of the common cytokine receptor gamma-chain in regulating IL-2-dependent, activation-induced CD8+ T cell death.
Dai Z; Arakelov A; Wagener M; Konieczny BT; Lakkis FG
J Immunol; 1999 Sep; 163(6):3131-7. PubMed ID: 10477579
[TBL] [Abstract][Full Text] [Related]
20. Altered peptide ligands act as partial agonists by inhibiting phospholipase C activity induced by myasthenogenic T cell epitopes.
Faber-Elmann A; Paas-Rozner M; Sela M; Mozes E
Proc Natl Acad Sci U S A; 1998 Nov; 95(24):14320-5. PubMed ID: 9826698
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
